- Home
- NMI vs CCCC Comparison
NMI vs CCCC Comparison
Compare NMI & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMI | CCCC |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.1M | 240.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NMI | CCCC |
|---|---|---|
| Price | $10.02 | $2.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 28.4K | ★ 1.4M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 4.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,108,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.30 | $1.09 |
| 52 Week High | $10.05 | $4.70 |
Technical Indicators
Market Signals| Indicator | NMI | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 49.35 | 49.03 |
| Support Level | $9.95 | $2.50 |
| Resistance Level | $10.15 | $2.69 |
| Average True Range (ATR) | 0.07 | 0.18 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 50.00 | 23.86 |
Price Performance
Historical ComparisonAbout NMI Nuveen Municipal Income Fund Inc.
Nuveen Municipal Income Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations issued by state and local government authorities or certain U.S. territories.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.